NCT00709527已完成1 期
A Phase 1 Ascending Dose And Parallel Group Trial To Establish The Safety, Tolerability And Pharmacokinetic Profile of Multiple Intravitreous Injections of ARC1905 (Anti-C5 Aptamer) Given In Combination With Multiple Doses of Lucentis® 0.5 mg/Eye In Subjects With Neovascular Age-Related Macular Degeneration
Ophthotech Corporation1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2008年10月16日最近更新:
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Presence of any dose-limiting toxicity (DLT), safety endpoints include adverse events, vital signs, ophthalmic variables and outcomes
研究概览
简要总结
The objectives of this study are to evaluate the safety, tolerability, and pharmacokinetic profile of multiple doses of ARC1905 intravitreous injection when administered in combination with multiple doses of Lucentis® 0.5 mg/eye, or with one induction dose of Lucentis 0.5 mg/eye in subjects with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD).
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subfoveal choroidal neovascularization (CNV) due to AMD (i.e., predominately classic, minimally classic or occult no classic) as documented by fluorescein angiogram.
排除标准
- •Previous or concomitant therapy with intravitreous corticosteroids.
- •Any of the following underlying diseases including:
- •Diabetic retinopathy
- •History or evidence of severe cardiac disease (e.g., NYHA Functional Class III or IV), history or clinical evidence of unstable angina, acute coronary syndrome, myocardial infarction or revascularization within last 6 months, ventricular tachyarrythmias requiring ongoing treatment.
- •History or evidence of clinically significant peripheral vascular disease, such as intermittent claudication or prior amputation.
- •Clinically significant impaired renal (serum creatinine >2.5 mg/dl or s/p renal transplant or receiving dialysis) or hepatic function. Patients with results outside these ranges may be enrolled in consultation with Ophthotech.
- •Stroke (within 12 months of trial entry).
- •Any major surgical procedure within one month of trial entry.
- •Previous therapeutic radiation in the region of the study eye.
- •Any treatment with an investigational agent in the past 60 days for any condition.
- •Women who are pregnant or nursing.
- •Known serious allergies to the fluorescein dye used in angiography, to the components of the ranibizumab formulation, or to the components of the ARC1905 formulation.
研究组 & 干预措施
1
Experimental
干预措施: Avacincaptad Pegol (Drug)
结局指标
主要结局
Presence of any dose-limiting toxicity (DLT), safety endpoints include adverse events, vital signs, ophthalmic variables and outcomes
时间窗: 2 years
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Phase 1 Ascending and Parallel Group Trial to Establish the Safety, Tolerability and Pharmacokinetics Profile of Volociximab (Alpha 5 Beta 1 Integrin Antagonist) in Subjects With Neovascular Age- Related Macular DegenerationAge-related Macular DegenerationNCT00782093Ophthotech Corporation63
已完成
1 期
A Phase 1, Safety, Tolerability and Pharmacokinetic Profile of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) in Subjects With Neovascular Age-Related Macular DegenerationAge-related Macular DegenerationNCT00569140Ophthotech Corporation18
已完成
1 期
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of MBX 1416 in Healthy SubjectsPostbariatric HypoglycemiaNCT06036784MBX Biosciences69
已完成
1 期
Safety and Tolerability Study of Xisomab 3G3 in Healthy Adult SubjectsThrombosisNCT03097341Aronora, Inc.21
已完成
1 期
A Phase 1b Study to Assess the Safety, Tolerability, PK and PD of MG1113 in Hemophilia PatientHemophiliaNCT05493631GC Biopharma Corp15